{
    "clinical_study": {
        "@rank": "35328", 
        "arm_group": {
            "arm_group_label": "Picosecond Laser System", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Pico laser is effective and safe in the\n      treatment of benign pigmented lesions."
        }, 
        "brief_title": "Picosecond Laser for Ttreatment of Benign Pigmented Lesions", 
        "condition": "Benign Pigmented Lesions", 
        "detailed_description": {
            "textblock": "The Investigational device is a dual wavelength laser system developed for treatment of\n      pigmented lesions and for tattoo removal. The base unit is a GentleMax system modified to\n      emit light at wavelengths of 532 and 1064 nm and deliver pulse energy up to 400mJ, and pulse\n      duration of 700 ps."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Has Fitzpatrick skin type  I-VI\n\n          2. Has unwanted benign pigmented lesions including but not limited to  solar lentigines,\n             freckles, caf\u00e9 au lait, melasma, New of Ota, Nevus of Ito, and\n                                                                       hyperpigmentation,   and\n             wishes to undergo laser treatments to remove them\n\n          3. Is willing to sign an informed consent form to participate in the study\n\n          4. Is willing to comply with all requirements of the study including being photographed,\n             following post treatment care and attending all treatment and follow up visits\n\n        Exclusion Criteria:\n\n          1. Is hypersensitive to light exposure\n\n          2. Has an active sun tan\n\n          3. Has active localized or systemic infection\n\n          4. Is taking medication(s) for which sunlight is a contraindication\n\n          5. Has a history of squamous cell carcinoma or melanoma\n\n          6. Has a history of keloid scarring\n\n          7. Has used oral isotretinoin (Accutane\u00ae) within 12 months of initial treatment or plans\n             on using during the course of the study.  Note: Skin must regain its normal degree of\n             moisture prior to treatment, e.g., lack of noticeable skin flaking, skin peeling and\n             skin surface roughness.\n\n          8. Has had a laser procedure, a peel or has used lightening creams in the area to be\n             treated  with in the past six months\n\n          9. Has a history of immunosuppression/immune deficiency disorders (including HIV\n             infection or AIDS) or use of immunosuppressive medications\n\n         10. Is female and pregnant is currently breast feeding or planning a pregnancy during the\n             study period\n\n         11. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine\n\n         12. Subjects with pigmented lesions that are considered not acceptable by the study\n             doctor or any condition that, in the study doctor's opinion, would make it unsafe to\n             treat."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146820", 
            "org_study_id": "DHF13661"
        }, 
        "intervention": {
            "arm_group_label": "Picosecond Laser System", 
            "description": "Picosecond Laser System for the Treatment of Pigmented Lesions", 
            "intervention_name": "GentleMax system", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Pigmented Lesions, Skin Pigment, Picosecond Laser, Syneron", 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Sara Loehmer", 
                    "phone": "415-923-3377"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Laser and Cosmetic Dermatology"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "samantha@hhlchan.com", 
                    "last_name": "Samantha Shek, MD", 
                    "phone": "852-2290-1720"
                }, 
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "China"
                    }, 
                    "name": "Hong Kong Dermatology and Laser Centre"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "China"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "LASER TREATMENT OF BENIGN PIGMENTED LESIONS WITH A DUAL WAVELENGTH PICOSECOND LASER", 
        "overall_contact": {
            "email": "Shlomit.Mann@syneron.com", 
            "last_name": "Shlomit Mann", 
            "phone": "972-73-244-2200", 
            "phone_ext": "347"
        }, 
        "overall_official": {
            "affiliation": "Syneron Medical Ltd.", 
            "last_name": "Shlomit Mann", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Global percentage of pigment clearance evaluated by blinded observers using post treatment photographs compared to baseline photographs.", 
            "measure": "Global percentage of pigment clearance", 
            "safety_issue": "No", 
            "time_frame": "3 months post the final treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146820"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events will be evaluated immediately after and before each subsequent laser treatment and will be based on the incidence and severity of side effects caused by the laser treatments.", 
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Syneron Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Syneron Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}